Notably, previous studies have also demonstrated the efficacy of the PD-1 inhibitor plus doxorubicin in UPS and dedifferentiated liposarcoma (Tian et al., 2020a; Pollack et al., 2020; Livingston et al., 2021). This evidence concerns the gene PDCD1 and liposarcoma.